Evidence map›Paper›PMID 40632444›Full record

ReviewCurrent treatment options in oncology2025

The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.

Imperia Nuzzolese, Stefano Cavalieri, Lisa F Licitra, Salvatore Alfieri

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Imperia NuzzoleseHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy. imperia.nuzzolese@istitutotumori.mi.it.
Stefano CavalieriHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy.
Lisa F LicitraHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy.
Salvatore AlfieriHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-melanoma skin cancers (NMSCs), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in the Caucasian population. While localized disease has a high cure rate, advanced cases pose therapeutic challenges. The introduction of immune checkpoint inhibitors (ICIs) has revolutionized treatment; however, resistance and contraindications necessitate alternative strategies. Epidermal growth factor receptor (EGFR) inhibition, particularly with cetuximab, has emerged as a potential therapeutic option in cSCC. This review evaluates the role of cetuximab in NMSC, focusing on clinical efficacy, safety, and emerging therapeutic strategies. A literature search was conducted using PubMed and clinical trial databases to identify relevant studies on cetuximab in advanced cSCC and BCC. The review discusses its use as monotherapy, in combination with radiotherapy or chemotherapy, and in the post-ICI setting. Despite the dominance of ICIs in advanced cSCC, cetuximab remains a valuable option, particularly for patients with ICI failure or contraindications. Its role as a radiosensitizer and its potential combination with immunotherapy warrant further investigation. Future studies should clarify optimal sequencing and combination strategies to improve patient outcomes.

Indexed as

Antineoplastic Agents, ImmunologicalBasal Cell CarcinomaCetuximabSkin NeoplasmsCarcinoma, Squamous CellCombined Modality TherapyErbB ReceptorsHumansImmune Checkpoint InhibitorsMolecular Targeted TherapyTreatment OutcomeAntineoplastic Agents, ImmunologicalCetuximabErbB ReceptorsImmune Checkpoint InhibitorsBasal cell carcinomaCetuximabCutaneous squamous cell carcinomaEGFR inhibitorsEpidermal growth factor receptorImmunotherapy resistanceNon-melanoma skin cancerTargeted therapy

Identifiers

PMID40632444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.